CA Healthcare Acquisition Corp.
CAHC
NASDAQ Capital Market9.94
USD
-0.03
- -
CA Healthcare Acquisition Corp.
CAHC
(NASDAQ Capital Market)
Recent
price
9.94
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CA Healthcare Acquisition Corp. (CAHC) is a blank check company focused on effecting a merger, share exchange, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the healthcare sector including healthcare services, healthcare information technology, care management, behavioral health, medical devices, diagnostics, pharma services, health and wellness, specialty pharmacy, medical distribution, and cost containment. The company offers no current operational products or services beyond its SPAC structure, which provides flexible capital and value-added management support to high-growth healthcare targets capable of 20%+ year-over-year revenue expansion and public market readiness. CAHC was founded in 2020 and is headquartered at 99 Summer Street, Suite 200, Boston, Massachusetts. In September 2021, CAHC completed a merger with LumiraDx Limited, a point-of-care diagnostics company, through which LumiraDx assumed CAHC's public listing on Nasdaq under the new ticker LMDX for common shares and LMDXW for warrants, while CAHC shares were effectively delisted following the business combination. As of December 2025, no further merger, acquisition, or business combination has been announced or completed by CAHC subsequent to the LumiraDx transaction, and the company maintains its blank check status with active trading of units (CAHCU) and warrants (CAHCW) on Nasdaq amid ongoing extensions potentially to December 2025. CAHC operates globally with a primary investment focus on U.S. and Canadian healthcare opportunities, led by CEO Larry J. Neiterman and supported by advisors from Covington Associates and Pleasant Bay Capital Partners.
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
CA Healthcare Acquisition Corp. and LumiraDx Limited Announce Effectiveness of Registration Statement and September 28, 2021 Special Meeting to Approve Business Combination
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp